Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nimodipine - Grace Therapeutics

Next Previous
Drug Profile

Nimodipine - Grace Therapeutics

Alternative Names: GTX 104; Nimodipine intravenous - Grace Therapeutics

Latest Information Update: 10 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grace Therapeutics
  • Class Antihaemorrhagics; Antihypertensives; Dihydropyridines; Esters; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Subarachnoid haemorrhage
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Subarachnoid haemorrhage

Most Recent Events

  • 29 Jul 2026 Grace Therapeutics receives minutes of Type A Meeting from US FDA for nimodipine for Subarachnoid haemorrhage
  • 08 May 2026 Grace Therapeutics intends to resubmit the New Drug Application to the US FDA for nimodipine for Subarachnoid haemorrhage
  • 23 Apr 2026 Grace Therapeutics intends to request a Type A meeting with the US FDA to clarify the path forward and determine the appropriate next steps on the CRL for the New Drug Application (NDA) for nimodipine for Subarachnoid haemorrhage

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top